Sharma Shweta, Hussain Showket, Soni Kartik, Singhal Pallavi, Tripathi Richa, Ramachandran V G, Sharma Sonal, Das Shukla, Pillai Beena, Bharadwaj Mausumi
Division of Molecular Genetics & Biochemistry, Institute of Cytology & Preventive Oncology, I-7 Sector 39, Noida, 201301, India.
Department of Microbiology, UCMS & GTB Hospital, Dilshad Garden, New Delhi, India.
Tumour Biol. 2016 Apr;37(4):4585-95. doi: 10.1007/s13277-015-4248-7. Epub 2015 Oct 27.
This study aimed to investigate the role of miRNAs in HPV-mediated cervical pre-cancer and cancer cases in Indian population. We analysed the HPV infection and its genotypes in uterine cervical pre-cancer (n = 80), cancer (n = 200) and normal cervical samples (n = 150) by consensus sequence PCR followed by type specific PCRs. Also, microRNA profiling was done in a subset of cervical pre-cancer (n = 20), cancer cases (n = 50) and normal samples (n = 30) by real-time quantitative PCR (qRT-PCR). The prevalence of HPV infection in pre-cancer was found to be 81 % (65/80) and 94 % (188/200) in cancer cases, with most predominant high-risk HPV type-16 (HR-HPV-16) in 83 % of cancer and 91 % of pre- cancer cases, respectively. Whereas in controls, the HPV infection was found to be very low (5 %). The miRNA profiling revealed that in cervical pre-cancer, 100 miRNAs were significantly (p < 0.001) differentially expressed with 70 miRNAs upregulated and 30 miRNAs downregulated. In cervical cancer cases, 383 miRNA were found to be differentially expressed (p < 0.001), of which 350 miRNAs were upregulated and 33 miRNAs were downregulated. We also observed that 182 miRNAs were differentially expressed (p < 0.001) in HPV-16/18-positive (SiHa/HeLa) cell lines compared with HPV-negative (C33A) cell line. In addition, we identified the novel microRNAs such as miR-892b, miR-500, miR-888, miR-505 and miR-711 in cervical precancerous lesions and cervical cancer cases in Indian population. Taken together, the study demonstrates a crucial role of microRNAs in cervical cancer, which may serve as potential early diagnostic markers for cervical carcinogenesis.
本研究旨在调查微小RNA(miRNA)在印度人群中HPV介导的宫颈上皮内瘤变及宫颈癌病例中的作用。我们通过一致性序列PCR及随后的型特异性PCR分析了子宫颈上皮内瘤变(n = 80)、癌症(n = 200)和正常宫颈样本(n = 150)中的HPV感染情况及其基因型。此外,通过实时定量PCR(qRT-PCR)对一部分宫颈上皮内瘤变(n = 20)、癌症病例(n = 50)和正常样本(n = 30)进行了微小RNA谱分析。结果发现,上皮内瘤变中HPV感染率为81%(65/80),癌症病例中为94%(188/200),其中最主要的高危HPV 16型(HR-HPV-16)分别在83%的癌症病例和91%的上皮内瘤变病例中出现。而在对照组中,HPV感染率非常低(5%)。微小RNA谱分析显示,在宫颈上皮内瘤变中,100种微小RNA有显著差异表达(p < 0.001),其中70种微小RNA上调,30种微小RNA下调。在宫颈癌病例中,发现383种微小RNA有差异表达(p < 0.001),其中350种微小RNA上调,33种微小RNA下调。我们还观察到,与HPV阴性(C33A)细胞系相比,HPV-16/18阳性(SiHa/HeLa)细胞系中有182种微小RNA有差异表达(p < 0.001)。此外,我们在印度人群的宫颈上皮内瘤变和宫颈癌病例中鉴定出了新型微小RNA,如miR-892b、miR-500、miR-888、miR-505和miR-711。综上所述,该研究证明了微小RNA在宫颈癌中起关键作用,其可能作为宫颈癌发生潜在的早期诊断标志物。